Filtered By:
Condition: Hyperactivity

This page shows you your search results in order of date.

Order by Relevance | Date

Total 2031 results found since Jan 2013.

ADHD Med Errors Among Kids Have Surged in Last 2 Decades
Medication errors among children who take drugs to treat attention deficit hyperactivity disorder (ADHD) reported to U.S. poison control centers increased by nearly 300% over a 22-year period, a new study published in the journal Pediatrics has found.
Source: WebMD Health - September 20, 2023 Category: Consumer Health News Source Type: news

Peer victimization in preadolescent children with ADHD: a controlled follow-up study - Örengül AC, Meral Y, Goker H, Orem MS, Zorlu A, Ozkececi Cifterler HH.
INTRODUCTION: The present study examines bullying and its psychological consequences in school age children with and without attention deficit hyperactivity disorder (ADHD). METHOD: The sample consisted of 34 children with ADHD and 36 children with...
Source: SafetyLit - September 19, 2023 Category: International Medicine & Public Health Tags: Age: Infants and Children Source Type: news

Cases of Pediatric Therapeutic Errors Related to ADHD Meds on the Rise
MONDAY, Sept. 18, 2023 -- From 2000 to 2021, there was an almost 300 percent increase in the annual frequency of cases of pediatric out-of-hospital therapeutic errors related to attention-deficit/hyperactivity disorder (ADHD) medications, according...
Source: Drugs.com - Pharma News - September 18, 2023 Category: Pharmaceuticals Source Type: news

ADHD Drug Errors Among Kids Have Quadrupled in 20 Years
MONDAY, Sept. 18, 2023 -- Over 3 million American children now take medication for attention-deficit/hyperactivity disorder (ADHD), but new research shows medication errors have spiked nearly 300% in the past two decades for these kids. The increase...
Source: Drugs.com - Daily MedNews - September 18, 2023 Category: General Medicine Source Type: news

Delayed-Release ADHD Therapy Slightly Mitigates Slowed Growth in Kids
(MedPage Today) -- NASHVILLE -- Youth with attention-deficit/hyperactivity disorder (ADHD) saw mildly different growth trajectories with certain popular medications, researchers reported. Compared with youth prescribed lisdexamfetamine dimesylate...
Source: MedPage Today Neurology - September 10, 2023 Category: Neurology Source Type: news

ADHD Is Independent Risk Factor for Psychiatric Disorders
THURSDAY, Sept. 7, 2023 -- Attention-deficit hyperactivity disorder (ADHD) is an independent risk factor for certain psychiatric disorders, including anorexia nervosa and major depressive disorder, according to a study published online Sept. 5 in...
Source: Drugs.com - Pharma News - September 7, 2023 Category: Pharmaceuticals Source Type: news

Increased anxiety and depression among collegiate athletes with comorbid ADHD and history of concussion - Moore RD, Kay JJM, Gunn B, Harrison AT, Torres-McGehee T, Pontifex MB.
BACKGROUND: Attention Deficit Hyperactivity Disorder (ADHD) is prevalent among student-athletes when compared to the general population. Mental health disruptions (i.e., depression or anxiety) are common among student-athletes, and risk of experiencing dep...
Source: SafetyLit - September 6, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

ADHD: What Parents Need to Know
MONDAY, Sept. 4, 2023 -- Lots of children and adolescents have the condition known as ADHD, or attention-deficit/hyperactivity disorder. What should parents know? A number of treatments exist to help with functioning, including medications approved...
Source: Drugs.com - Daily MedNews - September 4, 2023 Category: General Medicine Source Type: news

Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
DUBLIN, Aug. 31, 2023 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that its Specialty Generics segment, operating as SpecGx LLC, received approval on August 25, ... Biopharmaceuticals, Generics, FDA Mallinckrodt, SpecGx, lisdexamfetamine, ADHD
Source: HSMN NewsFeed - August 31, 2023 Category: Pharmaceuticals Source Type: news

Systematic review of environmental and psychosocial risk factors associated with attention deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder in children and adolescents - Elbagir R, Faisal M, O'Hanharan S.
BACKGROUND: In the majority of cases, attention deficit hyperactivity disorder (ADHD) is accompanied by one or more comorbid disorders, with the oppositional defiant disorder (ODD) being one of the most frequently diagnosed comorbid disorders. There is a l...
Source: SafetyLit - August 31, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news

On Money, ADHD Diagnosis Can Be Revelatory
After racking up $15,000 in debt, Ellyce Fulmore was diagnosed with A.D.H.D. in December 2020.Credit...Todd Korol for The New York Times A diagnosis of attention deficit hyperactivity disorder in adulthood has solved a mystery for some women, helping them get control over their finances. For Women…#ellycefulmore #adhd #toddkorol #dopamines #edwardmhallowell #hallowelladhdcenters #tiktok #nt #additude
Source: Reuters: Health - August 31, 2023 Category: Consumer Health News Source Type: news

FDA OKs ADHD Generics; Flotation Therapy; Civilians Respond to Distress Calls
(MedPage Today) -- The FDA approved the first generic forms of lisdexamfetamine dimesylate (Vyvanse) capsules and chewables to treat attention deficit-hyperactivity disorder (ADHD) in patients 6 years and older, as well as moderate to severe binge...
Source: MedPage Today Psychiatry - August 30, 2023 Category: Psychiatry Source Type: news

FDA Approves First Generics for Vyvanse
August 28, 2023 -- FDA has approved several first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for attention-deficit/hyperactivity disorder (ADHD) in patients six years and older and moderate to severe binge-eating...
Source: Drugs.com - Daily MedNews - August 28, 2023 Category: General Medicine Source Type: news

Risk factors of suicidal spectrum behaviors in adults and adolescents with attention-deficit / hyperactivity disorder - a systematic review - Austgulen A, Skram NKG, Haavik J, Lundervold AJ.
INTRODUCTION: Adolescents and adults with attention-deficit/hyperactivity disorder (ADHD) are at increased risk of suicidal spectrum behaviors (SSBs). However, there is limited knowledge about risk factors triggering SSBs in this group of people. O...
Source: SafetyLit - August 26, 2023 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news

Treating and Dealing with ADHD
Studies show that the number of children diagnosed with attention-deficit/hyperactivity disorder (ADHD) continues to rise. The FDA has approved two types of medications – stimulants and non-stimulants – to help reduce the symptoms of ADHD and improve functioning in children as young as age 6.
Source: FDA Consumer Health Information Updates - August 23, 2023 Category: Consumer Health News Authors: FDA Source Type: news